share_log

6-K: Blenrep (Belantamab Mafodotin) Combinations in Multiple Myeloma Application Accepted for Review by the European Medicines Agency

6-K: Blenrep (Belantamab Mafodotin) Combinations in Multiple Myeloma Application Accepted for Review by the European Medicines Agency

Blenrep(Belantamab Mafodotin)聯合療法治療多發性骨髓瘤的申請獲歐洲藥品管理局受理審查
美股sec公告 ·  07/19 07:11
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息